Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
24 participants
INTERVENTIONAL
2007-08-31
2010-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brostallicin
Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically confirmed myxoid liposarcoma.
3. Patients with metastatic and/or unresectable myxoid liposarcoma that is progressive and standard curative measures do not exist or are no longer effective.
4. Patient has measurable tumor on CT, spiral CT, or MRI scan that meet RECIST criteria.
5. Age ≥18 years
6. Karnofsky performance status (KPS) ≥ 70% (see Appendix III).
7. Life expectancy of at least 3 months.
8. Acceptable liver function:
* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* AST (SGOT), ALT (SGPT) and alkaline phosphatase ≤ 2.5 times ULN (if liver metastases are present, then ≤ 5 × ULN is allowed).
9. Acceptable renal function: For all patients serum creatinine within normal limits, OR calculated creatinine clearance ≥ 60 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal.
10. Acceptable hematologic status:
* Absolute neutrophil count (ANC) ≥ 1500 cells/mm(3) (1.5 ×10(9)/L)
* Platelet count ≥ 100,000 platelet/mm(3) (100 ×10(9)/L)
* Hemoglobin ≥ 9 g/dL.
Exclusion Criteria
* Chemotherapy, major surgery, significant traumatic injury, or irradiation, whether conventional or investigational within 28 days
* Mitomycin-C or nitrosurea within 42 days.
* ET-743 at any time (Stage 1 only).
2. Patients heavily pretreated with chemotherapy and radiation, defined as follows:
* ≥ 12 cycles of an alkylating agent-containing regimen, or
* \> 2 cycles carboplatin, or
* \> 2 cycles mitomycin C, or
* irradiation to 25% of bone marrow-containing areas, or
* high-dose chemotherapy requiring hematopoietic stem-cell reinfusion.
3. Known hypersensitivity to any study drug component.
4. Uncontrolled brain metastases in the judgement of the Investigator.
5. Abnormal cardiac or cardiovascular function, or serious cardiac illness or medical condition in the previous 6 months including, but not confined to:
* New York Heart Association (NYHA) grade 2 or higher congestive heart failure (CHF) or who has had angioplasty or placement of coronary stents within the previous 6 months
* Myocardial infarction within the past 6 months
* High-risk uncontrolled arrhythmias
* Angina pectoris that requires antianginal medication
* Has clinically significant valvular heart disease
* Evidence of transmural infarction on ECG
* Poorly controlled hypertension (e.g., blood pressure: systolic \>180 mm Hg or diastolic \>100 mm Hg).
6. Pregnant or lactating females. All patients (males and females) who are fertile must agree to use an effective barrier method of birth control (i.e., latex condom, diaphragm, cervical cap, etc) to avoid pregnancy.
7. Not recovered from acute toxicity of all previous therapy prior to enrollment.
8. History of prior malignancies within 3 years, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast.
9. Any evidence of serious and/or unstable pre-existing medical, psychiatric, or other condition (including laboratory abnormalities) that could interfere with patient safety or obtaining informed consent.
10. Any active uncontrolled infection including AIDS, hepatitis B or C.
11. Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow up schedule.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Systems Medicine LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cell Therapeutics, Inc. (Systems Medicine, L.L.C. is a wholly owned subsidiary of CTI)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jack Singer, M.D.
Role: STUDY_CHAIR
CTI BioPharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sarcoma Oncology Center
Santa Monica, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Study Sponsor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMI-BRS-202
Identifier Type: -
Identifier Source: org_study_id